Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 2
1956 1
1967 1
1973 1
1977 1
1982 1
1984 2
1985 1
1986 1
1987 2
1988 1
1989 2
1990 1
1991 1
1992 1
1993 3
1995 1
1996 2
1997 1
1998 4
2000 3
2001 1
2003 2
2006 1
2007 1
2009 4
2010 2
2011 2
2012 1
2013 1
2014 1
2015 1
2016 4
2017 1
2018 1
2019 3
2021 4
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Results by year

Filters applied: . Clear all
Page 1
Best Practices in Chronic Myeloid Leukemia Monitoring and Management.
Soverini S, De Benedittis C, Mancini M, Martinelli G. Soverini S, et al. Oncologist. 2016 May;21(5):626-33. doi: 10.1634/theoncologist.2015-0337. Epub 2016 Mar 31. Oncologist. 2016. PMID: 27032870 Free PMC article. Review.
: Optimal use of current therapeutic opportunities for chronic myeloid leukemia patients requires integration of clinical and laboratory monitoring. ...We also include a practical guide for pathologists and molecular biologists to best perform molecular testi …
: Optimal use of current therapeutic opportunities for chronic myeloid leukemia patients requires integration of clinic …
Genetic studies in the evaluation of myeloproliferative neoplasms.
Caponetti GC, Bagg A. Caponetti GC, et al. Semin Hematol. 2019 Jan;56(1):7-14. doi: 10.1053/j.seminhematol.2018.05.004. Epub 2018 May 28. Semin Hematol. 2019. PMID: 30573049 Review.
Myeloproliferative neoplasms that include the specific entities of chronic myeloid leukemia, chronic neutrophilic leukemia, polycythemia vera, essential thrombocythemia, and primary myelofibrosis are characterized by the clonal expansion of hematopoiet …
Myeloproliferative neoplasms that include the specific entities of chronic myeloid leukemia, chronic neutrophilic le …
Drug Repositioning for the Treatment of Hematologic Disease: Limits, Challenges and Future Perspectives.
Allegra A, Imbesi C, Bitto A, Ettari R. Allegra A, et al. Curr Med Chem. 2021;28(11):2195-2217. doi: 10.2174/0929867327999200817102154. Curr Med Chem. 2021. PMID: 33138750 Review.
Although the majority of studies on drug repositioning in hematology concern acute myeloid leukemia and multiple myeloma, numerous studies are present in the literature on the possibility of using these drugs also in other hematological diseases, such as acute lymphoblasti …
Although the majority of studies on drug repositioning in hematology concern acute myeloid leukemia and multiple myeloma, numerous st …
Assessing patient attitudes toward genetic testing for hereditary hematologic malignancy.
Johnson AQ, Bannon SA, Farach LS, Hyde SM, Hashmi SS, Wagner C, DiNardo CD. Johnson AQ, et al. Eur J Haematol. 2023 Jan;110(1):109-116. doi: 10.1111/ejh.13880. Epub 2022 Oct 21. Eur J Haematol. 2023. PMID: 36209474
Since 2003, more than 15 genes have been identified to predispose to hereditary hematologic malignancy (HHM). Although the yield of germline analysis for leukemia appears like that of solid tumors, genetic referrals in adults with leukemia remain underperformed. We …
Since 2003, more than 15 genes have been identified to predispose to hereditary hematologic malignancy (HHM). Although the yield of germline …
Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations.
Keskin D, Sadri S, Eskazan AE. Keskin D, et al. Drug Des Devel Ther. 2016 Oct 13;10:3355-3361. doi: 10.2147/DDDT.S85050. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27784993 Free PMC article. Review.
Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intolerance, as well as in the frontline setting in patients with chronic myeloid leukemia-chronic phase, and also in patients with advanced disease. ...Th …
Dasatinib is one of the second-generation tyrosine kinase inhibitors used in imatinib resistance and/or intolerance, as well as in the front …
Update on the biology and treatment options for hairy cell leukemia.
Jain P, Pemmaraju N, Ravandi F. Jain P, et al. Curr Treat Options Oncol. 2014 Jun;15(2):187-209. doi: 10.1007/s11864-014-0285-5. Curr Treat Options Oncol. 2014. PMID: 24652320 Free PMC article. Review.
Hairy cell leukemia (HCL) is an uncommon chronic leukemia of mature B cells. Leukemic B cells of HCL exhibit a characteristic morphology and immunophenotype and coexpress multiple clonally related immunoglobulin isotypes. ...However, approximately 30-40 % of …
Hairy cell leukemia (HCL) is an uncommon chronic leukemia of mature B cells. Leukemic B cells of HCL exhibit a characte …
Advances in the diagnosis and treatment of acute and chronic leukemia in Mexico.
Ruiz-Argüelles GJ. Ruiz-Argüelles GJ. Salud Publica Mex. 2016 Apr;58(2):291-5. doi: 10.21149/spm.v58i2.7799. Salud Publica Mex. 2016. PMID: 27557388 Review.
In the last 60 years, there have been substantial advances regarding the diagnosis and treatment of patients with acute and chronic leukemia in Mexico. Immunologic and molecular classifications of these diseases have improved both diagnosis and therapeutic ca …
In the last 60 years, there have been substantial advances regarding the diagnosis and treatment of patients with acute and chronic …
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.
Martí-Carvajal AJ, Anand V, Solà I. Martí-Carvajal AJ, et al. Cochrane Database Syst Rev. 2015 Jun 24;2015(6):CD008562. doi: 10.1002/14651858.CD008562.pub3. Cochrane Database Syst Rev. 2015. PMID: 26107113 Free PMC article. Review.
BACKGROUND: Disseminated intravascular coagulation (DIC) is an acquired syndrome characterized by systemic intravascular activation of coagulation, leading to deposition of fibrin in the bloodstream. It may occur in patients with acute and chronic leukemia and is pa …
BACKGROUND: Disseminated intravascular coagulation (DIC) is an acquired syndrome characterized by systemic intravascular activation of coagu …
Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.
Martí-Carvajal AJ, Simancas D, Cardona AF. Martí-Carvajal AJ, et al. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD008562. doi: 10.1002/14651858.CD008562.pub2. Cochrane Database Syst Rev. 2011. PMID: 21678379 Updated. Review.
BACKGROUND: Disseminated intravascular coagulation (DIC) is an acquired syndrome characterized by systemic intravascular activation of coagulation, leading to deposition of fibrin in the bloodstream, that may occur in patients with acute and chronic leukemia. OBJECT …
BACKGROUND: Disseminated intravascular coagulation (DIC) is an acquired syndrome characterized by systemic intravascular activation of coagu …
Diagnosis, treatment, and nursing care of patients with chronic leukemia.
Breed CD. Breed CD. Semin Oncol Nurs. 2003 May;19(2):109-17. doi: 10.1016/s0749-2081(03)00007-x. Semin Oncol Nurs. 2003. PMID: 12830735 Review.
OBJECTIVES: To provide an update on the impact of new information about the molecular biology of chronic leukemia and new treatment modalities available to patients. ...CONCLUSION: There has been significant progress in the diagnosis and management of chronic …
OBJECTIVES: To provide an update on the impact of new information about the molecular biology of chronic leukemia and new trea …
63 results